三阴性乳腺癌靶向治疗策略  

Targeted treatment strategies of three negative breast cancer

作　　者：韦凤[1] 唐林[1] 管晓翔[1] 

机构地区：[1]南京大学医学院临床学院(南京军区南京总医院)肿瘤内科,江苏南京210002

出　　处：《中华肿瘤防治杂志》2012年第2期157-160,共4页Chinese Journal of Cancer Prevention and Treatment

基　　金：国家自然科学基金(81141094;30870962)

摘　　要：目的:总结近期国内外三阴性乳腺癌的靶向治疗研究进展。方法:应用Medline、Pub Med、Web of science、CNKI数据库,以"三阴性乳腺癌、基底样乳腺癌和靶向治疗"为关键词,搜索近期发表的相关临床研究。共纳入文献30篇。结果:大量临床试验发现,靶向表皮生长因子受体(EGFR)抑制药西妥昔单抗(单克隆抗体)能明显提高TNBC患者的总反应率(ORR)、无进展生存期(PFS)、总生存期(OS)或临床获益(CB);血管内皮生长因子(VEGF)抑制药贝伐珠单抗(单克隆抗体)不能延长患者OS,但能显著延长MBC/ABC患者的PFS和ORR,索拉非尼(小分子抑制剂)能改善TNBC患者的PFS;腺苷核糖聚合酶(PARP)抑制药olaparib,能使BRCA1/2基因突变的TNBC患者获益。结论:随着对TNBC生物学行为的深入研究,新的靶点不断被发现、新的靶向药物陆续面市,使TNBC治疗策略更完善。OBJECTIVE： To summarize recent targeted treatment strategies of TNBC of domestic and oversea.METHODS： ＂triple-negative breast cancer,basal-like breast cancer and targeted therapy＂ as the Keywords,recently published clinical trials were searched from databases of Medline,Pub Med,Web of science,CNKI.Thirty papers were finally reviewed.RESULTS： Large clinical trials found that： cetuximab,one of epidermal growth factor receptor（EGFR） inhabitors,can greatly improve ORR,PFS,OS and CB of TNBC patients.As one of Vascular endothelial growth factor（VEGF） inhabitors,Avastin can significantly extend MBC/ABC patients＇ ORR and PFS and sorafenib（small molecule inhibitors） can prolong the PFS of TNBC patients.TNBC patients can get benefit from PARP inhabitor： olaparib.CONCLUSION： As advanced study of biological behavior of TNBC,new targets and drugs are discovered,so more TNBC patients will get greater benefit from better targeted treatment strategies.

关 键 词：乳腺肿瘤/药物疗法 靶向治疗 文献综述 

分 类 号：R737.9[医药卫生—肿瘤]